Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
14.68
+0.18 (1.21%)
Apr 23, 2026, 11:28 AM EDT - Market open
Amarin Corporation Employees
Amarin Corporation had 80 employees as of December 31, 2025. The number of employees decreased by 195 or -70.91% compared to the previous year.
Employees
80
Change (1Y)
-195
Growth (1Y)
-70.91%
Revenue / Employee
$2,670,575
Profits / Employee
-$484,975
Market Cap
307.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 80 | -195 | -70.91% |
| Dec 31, 2024 | 275 | 0 | - |
| Dec 31, 2023 | 275 | -90 | -24.66% |
| Dec 31, 2022 | 365 | -195 | -34.82% |
| Dec 31, 2021 | 560 | -440 | -44.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Grifols | 25,247 |
| Organon & Co. | 10,000 |
| Biogen | 7,500 |
| Scilex Holding Company | 30 |
AMRN News
- 8 days ago - Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 - GlobeNewsWire
- 2 months ago - This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease - GlobeNewsWire
- 3 months ago - US Supreme Court to hear 'skinny label' patent fight involving Amarin - Reuters
- 3 months ago - Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization - GlobeNewsWire
- 5 months ago - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients - GlobeNewsWire
- 6 months ago - Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 6 months ago - Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewsWire
- 8 months ago - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 - GlobeNewsWire